MedPath

ATACAND HCT

ATACAND HCT 16-12.5 () TABLETS, FOR ORAL USE ATACAND HCT 32-12.5 () TABLETS, FOR ORAL USE ATACAND HCT 32-25 TABLETS, FOR ORAL USE

Approved
Approval ID

d91152c4-66ba-466f-b4f9-0da628d42b1d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 7, 2020

Manufacturers
FDA

ANI Pharmaceuticals, Inc.

DUNS: 145588013

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Candesartan Cilexetil and Hydrochlorothiazide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62559-650
Application NumberNDA021093
Product Classification
M
Marketing Category
C73594
G
Generic Name
Candesartan Cilexetil and Hydrochlorothiazide
Product Specifications
Route of AdministrationORAL
Effective DateOctober 25, 2019
FDA Product Classification

INGREDIENTS (10)

CANDESARTAN CILEXETILActive
Quantity: 16 mg in 1 1
Code: R85M2X0D68
Classification: ACTIB
HYDROCHLOROTHIAZIDEActive
Quantity: 12.5 mg in 1 1
Code: 0J48LPH2TH
Classification: ACTIB
CARBOXYMETHYLCELLULOSE CALCIUMInactive
Code: UTY7PDF93L
Classification: IACT
HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3B
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT

Candesartan Cilexetil and Hydrochlorothiazide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62559-652
Application NumberNDA021093
Product Classification
M
Marketing Category
C73594
G
Generic Name
Candesartan Cilexetil and Hydrochlorothiazide
Product Specifications
Route of AdministrationORAL
Effective DateOctober 25, 2019
FDA Product Classification

INGREDIENTS (10)

FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
CANDESARTAN CILEXETILActive
Quantity: 32 mg in 1 1
Code: R85M2X0D68
Classification: ACTIB
HYDROCHLOROTHIAZIDEActive
Quantity: 25 mg in 1 1
Code: 0J48LPH2TH
Classification: ACTIB
CARBOXYMETHYLCELLULOSE CALCIUMInactive
Code: UTY7PDF93L
Classification: IACT
HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3B
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT

Candesartan Cilexetil and Hydrochlorothiazide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62559-651
Application NumberNDA021093
Product Classification
M
Marketing Category
C73594
G
Generic Name
Candesartan Cilexetil and Hydrochlorothiazide
Product Specifications
Route of AdministrationORAL
Effective DateOctober 25, 2019
FDA Product Classification

INGREDIENTS (9)

FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
CANDESARTAN CILEXETILActive
Quantity: 32 mg in 1 1
Code: R85M2X0D68
Classification: ACTIB
HYDROCHLOROTHIAZIDEActive
Quantity: 12.5 mg in 1 1
Code: 0J48LPH2TH
Classification: ACTIB
CARBOXYMETHYLCELLULOSE CALCIUMInactive
Code: UTY7PDF93L
Classification: IACT
HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3B
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ATACAND HCT - FDA Drug Approval Details